"if this submission results in another CRL then the CEO should be removed for ignoring the previous CRL."
... yes, & the CEO & every other officer of the company in a responsible position should duly expect an immense tidal wave of litigation, from every direction, that would decimate them.
V.
(i really don't think it will come to that.)
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-132
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |